Ticks can carry bacteria that cause Lyme disease. jwilkinson/iStock via Getty Images Plus
Mark Klempner, University of Massachusetts Medical School
Lyme disease has become an insidious epidemic in the United States. Caused by bacteria transmitted through the bite of an infected tick, it can lead to heart problems, meningitis or arthritis if left untreated. It is the most common tick-borne illness in the United States, and the Centers for Disease Control and Prevention estimates that around 475,000 people likely contract the disease each year.
Scientists, doctors and ecologists have worked for decades to slow the spread of Lyme and the blacklegged, or deer, ticks that carry the disease-causing bacteria. However, the ticks’ range continues to expand. Today, over 50% of the American population lives in an area where these ticks are found.
The U.S. Food and Drug Administration approved a vaccine against Lyme in 1998, but it was met by controversy and was pulled from the market three years later. Efforts continue today to create a human vaccine as well as to stop the spread of Lyme by other means, including using gene editing to immunize mice that can transmit the bacteria to ticks, killing deer and using pesticides to control ticks.
My colleagues and I have been working on a different kind of prevention: a yearly injection. I am an infectious diseases physician-scientist and have been studying and working toward preventing Lyme disease for much of my career. Our recent work on preventing Lyme disease has been conducted at University of Massachusetts Medical School’s MassBiologics, the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States.
Our method, known as Lyme PrEP, delivers a single anti-Lyme antibody directly to a person rather than triggering the patient’s own immune system to make many antibodies, as vaccines do. It is designed to be a seasonal shot that people can get once a year before tick season begins in April. We have published several peer-reviewed articles on this method, including on its success in mice and nonhuman primates.
In February 2021, we received approval from the FDA to proceed with the first human clinical trial of Lyme PrEP, and all of the volunteers in this trial have been enrolled and received the shot. Our goal for this study, also known as the phase 1 clinical trial, is to test the safety of the new medicine and determine how long it might stay in the bloodstream and prevent Lyme disease.
The preliminary results from the trial are very encouraging: They show that Lyme PrEP is safe and should be effective during the entire nine-month season when most people acquire Lyme disease.
In 1998, the FDA approved a Lyme vaccine composed of protein antigens from the surface of the Lyme bacteria, Borrelia burgdorferi.
A vaccine works by introducing proteins from the disease-causing agent into the body to trigger the body’s immune response, which includes making antibodies against bacterial proteins. Antibodies have been used to prevent and treat infectious diseases for over a century. In the case of the Lyme vaccine, it can take many months for the body to build up the necessary level of immunity to prevent infection. It also means that some of the antibodies induced by the vaccine can have “off-target” effects, or side effects.
The Lyme vaccine, known as LYMErix, largely reduced infections but was withdrawn from the market after three years because of limitations and controversy.
LYMErix needed to be administered by multiple injections over a year before immunity developed. Uncertainty about the length of immunity from the vaccine also raised questions of whether a booster shot would be regularly needed. Further, publicity about side effects such as arthritis, reported by some who had been vaccinated, contributed to its decline in popularity.
Today, a French biotech company, in collaboration with Pfizer, is attempting to develop a Lyme vaccine; it is currently in clinical trials.
Unlike a vaccine, Lyme PrEP uses a single human antibody, or blood protein, to kill the bacteria in the tick’s gut while the tick drinks its victim’s blood, before the bacteria can get into the human host.
Through our research, we realized that just one of the antibodies that the human body developed after multiple injections of the LYMErix vaccine was sufficient to prevent infection. So we identified which antibody led to immunity and tested it in animals, where it proved 100% effective.
Lyme PrEP is an antibody shot. Catherine Falls Commercial/Moment via Getty Images
These animal studies show Lyme PrEP gives protection immediately upon injection as it circulates through the blood. Unlike a vaccine, which induces many antibodies that may not contribute to protection but can cause side effects, this approach uses a single, defined antibody, thus reducing the risk of side effects.
Initial tests of a single injection of Lyme PrEP protected mice for several weeks.
Humans, however, need to be protected longer, likely for the approximately nine-month season when over 90% of cases occur. So far our phase 1 trial indicates that the shot will give protection for the necessary amount of time, but we will have to confirm that during the later phases of the clinical trials.
For the phase 1 trial we wanted to avoid testing the Lyme PrEP antibody on volunteers who may have already been exposed to the Lyme bacteria and have developed responses that could confuse the results. For that reason, initial testing took place in Nebraska in volunteers who have not been exposed to Lyme disease.
The next two phases of the clinical trial will test for safety and efficacy. We hope to complete these larger studies in late 2022. If all goes well, Lyme PrEP could become available to the public in 2023 or 2024.
This is an updated version of an article originally published on June 4, 2020.
Mark Klempner, Professor of Medicine and Executive Vice Chancellor for MassBiologics, University of Massachusetts Medical School
This article is republished from The Conversation under a Creative Commons license. Read the original article.
In The News
>WEATHER: Mark Rosenthal's 7-day forecast (:48). High of 53 today in Worcester
>TOP OF THE NEWS
-U.S. Marine from Worcester swept out to sea in waters at beach in Puerto Rico
-Worcester couple convicted of helping scam woman out of $3.2 million
-Sutton magician sentenced to more than 6 years in prison for child pornography offenses
-Driver sentenced to 4 1/2 to 5 1/2 years in Worcester drag-racing death of Jessica Simone
-Worcester 12-year-old donates hundreds of Easter Baskets to homeless children (2:13). Article
-Rally in Worcester for North High state champs on Saturday
-Longtime C.E.O. of Imperial Distributors to step down, be succeeded by president
-Rep. McGovern fundraiser in Worcester met with protests
-What is Good Friday? What the holy day means for Christians wordwide
-The Faces of Worcester: Principe Virtuez, business owner
-Unsolved: Worcester — Murder of Judith Viewig & disappearance of Deborah Quimby. Video (19:50). Audio (20:19)
>DINING OUT: Here's what is open locally on Easter Sunday
-ICYMI: Man to be indicted on murder charge in death of woman shot to death at Worcester massage parlor
-Samuel Peckham found guilty in 2022 Worcester road-rage killing
-Worcester interim police chief says department has harmed communities of color
-Worcester police's Alcohol Enforcement Unit aims to curb underage drinking
-See the rest of the day's Worcester news
>HOLDEN (brought to you by Lamoureux Ford): Rabies clinic on April 6th
-At Lamoureux Ford, our customers tell our story the best (1:56)
-Mountview Middle School honor roll
>THE BURBS (brought to you by North End Motor Sales): Driver arrested after allegedly causing bus crash in Barre (:22). Article
-Annual Easter Egg Hunt at Waters Farm on Saturday
-Grafton Public Library Spring Egg Hunt on Saturday
-Daily phone call program checks on elderly in Sturbridge
-Brilla Coffee set to open in downtown Gardner this year
-Berlin, Boylston look at new school numbers
-Nashoba approves budget with user fees
>BARS & BANDS: The Mayor's Live Music List for Friday
>SHOWTIME: Hanover Theatre unveils stellar 2024-25 Broadway Series
-Joyner Lucas reveals how young mother, daughter's tragic death impacted him
-Five Things to Do: Sympli Whitney, Jack Soreff, Zigmont and more ...
-Meet this year's Women Making History, shaping Worcester's future
-Clark professor’s award-winning documentary to be released this spring
-Tattoo, visual art intersect at Electric Haze Art Showcase
-Unity Radio (58:33): Black In Business
-WCCA-TV's Hidden Treasures No. 111 (28:19): Nick Zwirblia, third guest appearance
-WCCA-TV's Chandler Chat No. 418 (27:47): Warner Fletcher
>OBITUARIES: Tribute to Worcester native who opened multiple businesses on West Boylston Street
>SPORTS: Red Sox beat Mariners on Opening Day
-Celtics lose to Hawks, 123-122
-Steve Belichick razzes dad Bill: "I've got a job and he doesn't"
-Holy Cross women's assistant basketball coach Paige Corkins named W.B.C.A. Thirty Under 30 honoree
>CARS: Bertera has the all-star team to help you find your next Nissan car or truck (:39)
-Subaru recalls nearly 119,000 vehicles over air bag problem
>NATIONAL: Millions of Americans could soon lose home internet access
-South American "crime tourists" infiltrate at least half of U.S. states to target the rich
-Tragic: 8-year-old girl drowns after being sucked into "malfunctioning" pipe at hotel pool
>NEW ENGLAND: Mass. man gets 40 years for beating partner to death on a beach in Maine
-Driver hospitalized after slamming into hotel housing migrants in Marlborough
>COLLEGES: TV showrunner, writer to deliver Commencement address at her alma mater, WPI
-Anna Maria's Aleice Harmon finds happiness by helping children as she earns her B.S.W. degree
-Clark student: Why is Student Accessibility Services so inaccessible?
>TRAVEL (brought to you by Fuller RV & Rental): Ogunquit, Maine rated top vacation destination by Real Simple magazine
>BUSINESS: Central Mass. business by the numbers
-LPL Research: Navigating the strategic investing landscape
-Amazon pours $150 billions into data centers to handle expected A.I. boom
>SHOPPING: Free solar eclipse glasses from Warby Parker available April 1 in U.S.
>HOMES: Nantucket is so expensive, an "affordable" home now costs $1 million
>HEALTH: Doctor talks about link between neti pots, dangerous amoeba (2:56)
-F.D.A. approves drug that may help reverse a rare, fatal condition
>FOOD: Fast-food chains still serve meats containing antibiotics — here are the ones to watch out for
>TV/STREAMING: "Yellowstone" Season 5 Part 2 reportedly “already written,” filming to start “in a few weeks”
>MOVIES: Danny DeVito, Arnold Schwarzenegger have movie in works
>CELEBRITY: Arnold Schwarzenegger says he got a pacemaker fitted last week
>ANIMALS: Phone-sized kitten turns guy into a cat person (12:54)
>HISTORY: Former Odd Fellow's Building on Main Street in Worcester
>GOOD NEWS (brought to you by Bertera Nissan): Pilots taking flight to help animals
-Meanwhile, Mike Tyson is selling edibles shaped like an ear
Latest obituaries | | Thursday's highlights | | Today's horoscope | | Local Sports
Quick Links: Personalize your news | | Browse members | | Advertise | | Blogs | | Invite friends | | Videos
Animals | | Boston Sports | | Business | | Cars | | Celebrity | | Colleges | | Commute & Travel | | Crime | | Faith | | Food | | Good News | | Health | | History | | Homes | | Local Sports | | Lottery | | Movies | | National | | New England | | Politics | | Shopping & Deals | | SHOWTIME! | | TV & Streaming | | Weather